ZAP-70, IgVh, and cytogenetics for assessing prognosis in chronic lymphocytic leukemia

Cancer Biomarkers

Volumn 6, Issue 1, 2009, Pages 1-9

  Trojani, Alessandra ^a   Montillo, Marco ^a   Nichelatti, Michele ^a   Tedeschi, Alessandra ^a   Colombo, Chiara ^a   Veronese, Silvio ^a   Mura, Maria Angela ^a   Ricci, Francesca ^a   Scarpati, Barbara ^a   Colosimo, Anna ^a   Lodola, Milena ^a   Morra, Enrica ^a  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

Author keywords

Biomarkers; CLL; Cytogenetics; IgVh; ZAP 70

Indexed keywords

BIOLOGICAL MARKER; IMMUNOGLOBULIN HEAVY CHAIN; PROTEIN KINASE ZAP 70;

ADULT; AGED; ARTICLE; CANCER GROWTH; CHROMOSOME 11Q; CHROMOSOME 17P; CHROMOSOME 6Q; CHRONIC LYMPHATIC LEUKEMIA; CYTOGENETICS; FEMALE; GENE DELETION; GENE MUTATION; HUMAN; IMMUNOGLOBULIN VARIABLE REGION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; STATISTICAL MODEL; UNIVARIATE ANALYSIS;

ADULT; AGED; AREA UNDER CURVE; CELL SEPARATION; CYTOGENETICS; FEMALE; FLOW CYTOMETRY; GENE DELETION; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN VARIABLE REGION; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 77249090215     PISSN: 15740153     EISSN: None     Source Type: Journal    
DOI: 10.3233/CBM-2009-0114     Document Type: Article

References (37)

1. B. Austen, A. Skowronska, C. Baker, J.E. Powell, A. Gardiner, D. Oscier, A. Majid, M. Dyer, R. Siebert, A.M. Taylor, P.A. Moss and T. Stankovic, Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion, J Clin Oncol 25 (2007), 5448-5457.
2. J.L. Binet, F. Caligaris-Cappio, D. Catovsky, B. Cheson, T. Davis, G. Dighiero, H. Döhner, M. Hallek, P. Hillmen, M. Keating, E. Montserrat, T.J. Kipps and K. Rai, Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia, Blood 107 (2006), 859-861. (Pubitemid 43156279)
3. J.L. Binet, M. Lepoprier, G. Dighiero, D. Charron, P.D'Athis, G. Vaugier, H.M. Beral, J.C. Natali, M. Raphael, B. Nizet and J.Y. Follezou, A clinical staging system for chronic lymphocytic leukemia: prognostic significance, Cancer 40 (1977), 855-864.
4. J.C. Byrd, L. Smith, M.L. Hackbarth, I.W. Flinn, D. Young, J.H. Proffitt and N.A. Heerema, Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab, Cancer Res 63 (2003), 36-38.
5. B.D. Cheson, J.M. Bennett, M. Grever, N. Kay, M.J. Keating and S. O'Brien, National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment, Blood 87 (1996), 4990-4997.
6. M. Crespo, F. Bosch, N. Villamor, B. Bellosillo, D. Colomer, M. Rozman, S. Marće, A. Ĺopez-Guillermo, E. Campo and E. Montserrat, ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia, N Engl J Med 348 (2003), 1764-1775. (Pubitemid 36514707)
7. A. Cuneo, G.M. Rigolin, R. Bigoni, C. De Angeli, A. Veronese, F. Cavazzini, A. Bardi, M.G. Roberti, E. Tammiso, P. Agostini, M. Ciccone, M. Della Porta, A. Tieghi, L. Cavazzini, M. Negrini and G. Castoldi, Chronic lymphocytic leukemia with 6q-shows distinct hematological features and intermediate prognosis, Leukemia 18 (2004), 476-483.
8. F. Dicker, H. Herholz, S. Schnittger, A. Nakao, N. Patten, L. Wu, W. Kern and T. Haferlach, The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype, Leukemia 23 (2009), 117-124. Epub 9 Oct 2008.
9. J.D. Dickinson, J. Gilmore, J. Iqbal, W. Sanger, J.C. Lynch, J. Chan and P.J. Bierman, 11q22.3 deletion in B-chronic lymphocytic leukemia is specifically associated with bulky lymphadenopathy and ZAP-70 expression but not reduced expression of adhesion/cell surface receptor molecules, Leuk Lymph 47 (2006), 231-244.
10. G. Dighiero and T.J. Hamblin, Chronic lymphocytic leukaemia, Lancet 371 (2008), 1017-1029.
11. H. Döhner, K. Fischer, M. Bentz, K. Hansen, A. Benner, G. Cabot, D. Diehl, R. Schlenk, J. Coy and S. Stilgenbauer, p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias, Blood 85 (1995), 1580-1589.
12. H. Döhner, S. Stilgenbauer, A. Benner, E. Leupolt, A. Kröber, L. Bullinger, K. Döhner, M. Bentz, P. Lichter, Genomic aberrations and survival in chronic lymphocytic leukemia, N Engl J Med 343 (2000), 1910-1916. (Pubitemid 32064784)
13. S.R. Fink, S.A. Smoley, K.J. Stockero, S.F. Paternoster, E.C. Thorland, D.L. Van Dyke, T.D. Shanafelt, C.S. Zent, T.G. Call, N.E. Kay and G.W. Dewald, Loss of TP53 is due to rearrangements involving chromosome region 17p10 approximately p12 in chronic lymphocytic leukemia, Cancer Genet Cytogenet 167 (2006), 177-181.
14. First International Workshop on Chromosomes in Leukaemia: chromosomes in acute non-lymphocytic leukaemia, Br J Haematol 39 (1978), 311-316.
15. N. Gachard, A. Salviat, C. Boutet, C. Arnoulet, F. Durrieu, B. Lenormand, S. Leprêtre, S. Olschwang, F. Jardin, M. Lafage-Pochitaloff, D. Penther, D. Sainty, L. Reminieras, J. Feuillard and M.C. B́eńe, Multicenter study of ZAP-70 expression in patients with B-cell chronic lymphocytic leukemia using an optimized flow cytometry method, Haematologica 93 (2008), 215-223.
16. A. Gowda and J.C. Byrd, Use of prognostic factors in risk stratification at diagnosis and time of treatment of patients with chronic lymphocytic leukemia, Curr Opin Hematol 13 (2006), 266-272.
17. M. Hallek, Prognostic factors in chronic lymphocytic leukemia, Ann Oncol 19 (2008), Suppl 4: iv51-iv53.
18. T.J. Hamblin, Z.A. Davis and D.G. Oscier, Determination of how many immunoglobulin variable region heavy chain mutations are allowable in unmutated chronic lymphocytic leukaemia-long-term follow up of patients with different percentages of mutations, Br J Haematol 140 (2008), 320-323.
19. N.E. Kay and T.D. Shanafelt, Prognostic factors in Chronic Lymphocytic Leukemia, Curr Hematol Malign Rep 2 (2007), 49-55.
20. M.A. Kharfan-Dabaja, J.C. Chavez, K.A. Khorfan and J.Pinilla-Ibarz, Clinical and therapeutic implications of the mutational status of IgVH in patients with chronic lymphocytic leukemia, Cancer 113 (2008), 897-906. Review.
21. A. Krober, J. Bloehdorn, S. Hafner, A. Buhler, T. Seiler and D. Kienle, Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia, J Clin Oncol 24 (2006), 969-975.
22. A. Kröber, T. Seiler, A. Benner, L. Bullinger, E. Brückle, P. Lichter, H. Döhner and S. Stilgenbauer, V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia, Blood 100 (2002), 1410-1416. (Pubitemid 34864299)
23. L.C. Lau, P. Lim, Y.C. Lim, L.M. Teng, T.H. Lim, L.C. Lim, S.Y. Tan, S.T. Lim, W.G. Sanger and S.L. Tien, Occurrence of trisomy 12, t(14;18)(q32;q21), and t(8;14)(q24.1;q11.2) in a patient with B-cell chronic lymphocytic leukemia, Cancer Genet Cytogenet 185 (2008), 95-101.
24. F. Mitelman, (ed.), ISCN 1995: An International System for Human Cytogenetic Nomenclature, Basel, Switzerland: S. Karger, 1995.
25. C. Moreno and E. Montserrat, New prognostic markers in chronic lymphocytic leukemia, Bood Rev 22 (2008), 211-219.
26. J.A. Orchard, R.E. Ibbotson, Z. Davis, A.Wiestner, A. Rosenwald, P.W. Thomas, T.J. Hamblin, L.M. Staudt and D.G. Oscier, ZAP-70 expression and prognosis in chronic lymphocytic leukaemia, Lancet 363 (2004), 105-111.
27. D.G. Oscier, A.C. Gardiner, S.J. Mould, S. Glide, Z.A. Davis, R.E. Ibbotson, M.M. Corcoran, R.M. Chapman, P.WThomas, J.A. Copplestone, J.A. Orchard and T.J. Hamblin, Multivariate analysis of prognostic factors in CLL: clinical stage, IgVh gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors, Blood 100 (2002), 1177-1184.
28. F. Passam, V. Tachynopoulou, D. Skoumi, A. Tsompanakou, A. Stavropoulos-Giokas, C. Vadikolia, A. Anagnostopoulos and G. Paterakis, Feasibility of an easily applicable method of ZAP-70 measurement in chronic lymphocytic leukemia in the routine flow cytometry setting: A methodological approach, Ann Hematol 85 (2006), 795-805.
29. L.Z. Rassenti, L. Huynh, T.L. Toy, L. Chen, M.J. Keating, J.G. Gribben, D.S. Neuberg, I.W. Flinn, K.R. Rai, J.C. Byrd, N.E. Kay, A. Greaves, A.Weiss and T.J. Kipps, ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia, N Engl J Med 351 (2004), 893-901.
30. L.Z. Rassenti, S. Jain, M.J. Keating, W.G. Wierda, M.R. Grever, J.C. Byrd, N.E. Kay, J.R. Brown, J.G. Gribben, D.S. Neuberg, F. He, A.W. Greaves, K.R. Rai and T.J. Kipps, Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia, Blood 112 (2008), 1923-1930.
31. K.S. Reddy, Chronic lymphocytic leukaemia profiled for prognosis using a fluorescence in situ hybridisation panel, Br J Haematol 132 (2006), 705-722.
32. C. Rozman and E. Montserrat, Chronic lymphocytic leukemia, N Engl J Med 333 (1995), 1052-1057.
33. G. Schwarz, Estimating the dimension of a model, Annals of Statistics 6 (1978), 461-464.
34. L.G. Shaffer and N. Tommerup, An international system for human cytogenetic nomenclature (2005): recommendations of the International Standing Committee on Human Cytogenetic Nomenclature, Basel, Switzerland: S. Karger, 2005.
35. S. Stilgenbauer, L. Bullinger, A. Benner, K. Wildenberger, M. Bentz, K. Döhner, A.D. Ho, P. Lichter and H.Döhner, Incidence and clinical significance of 6q deletions in B cell chronic lymphocytic leukemia, Leukemia 13 (1999) 1331-1334.
36. S. Stilgenbauer, S. Sander, L. Bullinger, A. Benner, E. Leupolt, D. Winkler, A. Kröber, D. Kienle, P. Lichter and H. Döhner, Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival, Haematologica 92 (2007), 1242-1245.
37. J. Van Dongen, A.W. Langerak, M. Bruggemann, P. Evans, M. Hummel, F.L. Lavender, E. Delabesse, F. Davi, E. Schuuring, R. Garcia-Sanz, J. Van Krieken Droese, D. Gonzalez, C. Bastard, H.E. White, M. Spaargaren, M. Gonzalez, A. Parreira, J.L. Smith, G.J. Morgan, M. Kneba and E.A. Macintyre, Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferation: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936, Leukemia 17 (2003), 2257-2317.